Suppr超能文献

靶向术中放疗用于治疗乳腺导管原位癌

Targeted Intraoperative Radiotherapy for the Management of Ductal Carcinoma In Situ of the Breast.

作者信息

Rivera Ronald, Banks Alexandra, Casillas-Lopez America, Rashtian Afshin, Lewinsky Bernie, Sheth Pulin, Hovannesian-Larsen Linda, Brousseau David, Iyengar Geeta, Holmes Dennis R

机构信息

University of California, Los Angeles - David Geffen School of Medicine, Los Angeles, California.

California Hospital Medical Center - Los Angeles Center for Women's Health, Los Angeles, California.

出版信息

Breast J. 2016 Jan-Feb;22(1):63-74. doi: 10.1111/tbj.12516. Epub 2015 Nov 3.

Abstract

Multiple long-term studies have demonstrated a propensity for breast cancer recurrences to develop near the site of the original breast cancer. Recognition of this local recurrence pattern laid the foundation for the development of accelerated partial breast irradiation (APBI) approaches designed to limit the radiation treatment field to the site of the malignancy. However, there is a paucity of data regarding the efficacy of APBI in general, and intraoperative radiotherapy (IORT), in particular, for the management of ductal carcinoma in situ (DCIS). As a result, use of APBI, remains controversial. A prospective nonrandomized trial was designed to determine if patients with pure DCIS considered eligible for concurrent IORT based on preoperative mammography and contrast-enhanced magnetic resonance imaging (CE-MRI) could be successfully treated using IORT with minimal need for additional therapy due to inadequate surgical margins or excessive tumor size. Between November 2007 and June 2014, 35 women underwent bilateral digital mammography and bilateral breast CE-MRI prior to selection for IORT. Patients were deemed eligible for IORT if their lesion was ≤4 cm in maximal diameter on both digital mammography and CE-MRI, pure DCIS on minimally invasive breast biopsy or wide local excision, and considered resectable with clear surgical margins using breast-conserving surgery (BCS). Postoperatively, the DCIS lesion size determined by imaging was compared with lesion size and surgical margin status obtained from the surgical pathology specimen. Thirty-five patients completed IORT. Median patient age was 57 years (range 42-79 years) and median histologic lesion size was 15.6 mm (2-40 mm). No invasive cancer was identified. In more than half of the patients in our study (57.1%), MRI failed to detect a corresponding lesion. Nonetheless, 30 patients met criteria for negative margins (i.e., margins ≥2 mm) whereas five patients had positive margins (<2 mm). Two of the five patients with positive margins underwent mastectomy due to extensive imaging-occult DCIS. Three of the five patients with positive margins underwent successful re-excision at a subsequent operation prior to subsequent whole breast irradiation. A total of 14.3% (5/35) of patients required some form of additional therapy. At 36 months median follow-up (range of 2-83 months, average 42 months), only two patients experienced local recurrences of cancer (DCIS only), yielding a 5.7% local recurrence rate. No deaths or distant recurrences were observed. Imaging-occult DCIS is a challenge for IORT, as it is for all forms of breast-conserving therapy. Nonetheless, 91.4% of patients with DCIS were successfully managed with BCS and IORT alone, with relatively few patients requiring additional therapy.

摘要

多项长期研究表明,乳腺癌复发倾向于在原乳腺癌部位附近发生。对这种局部复发模式的认识为加速部分乳腺照射(APBI)方法的发展奠定了基础,该方法旨在将放射治疗范围限制在恶性肿瘤部位。然而,关于APBI总体疗效的数据较少,尤其是术中放疗(IORT)在导管原位癌(DCIS)治疗方面的数据。因此,APBI的使用仍存在争议。一项前瞻性非随机试验旨在确定,基于术前乳腺钼靶和对比增强磁共振成像(CE-MRI)被认为符合同时进行IORT条件的纯DCIS患者,是否可以通过IORT成功治疗,且因手术切缘不足或肿瘤过大而需要额外治疗的需求最小。2007年11月至2014年6月期间,35名女性在入选IORT之前接受了双侧数字化乳腺钼靶和双侧乳腺CE-MRI检查。如果患者的病变在数字化乳腺钼靶和CE-MRI上最大直径均≤4 cm,在微创乳腺活检或广泛局部切除时为纯DCIS,并且使用保乳手术(BCS)被认为可切除且手术切缘清晰,则被认为符合IORT条件。术后,将影像学确定的DCIS病变大小与手术病理标本获得的病变大小和手术切缘状态进行比较。35名患者完成了IORT。患者中位年龄为57岁(范围42 - 79岁),组织学病变中位大小为15.6 mm(2 - 40 mm)。未发现浸润性癌。在我们研究的超过一半患者(57.1%)中,MRI未能检测到相应病变。尽管如此,30名患者符合切缘阴性标准(即切缘≥2 mm),而5名患者切缘阳性(<2 mm)。5名切缘阳性患者中有2名因广泛的影像学隐匿性DCIS接受了乳房切除术。5名切缘阳性患者中有3名在后续全乳照射之前的后续手术中成功进行了再次切除。共有14.3%(5/35)的患者需要某种形式的额外治疗。在中位随访36个月(范围2 - 83个月,平均42个月)时,只有2名患者出现了癌症局部复发(仅DCIS),局部复发率为5.7%。未观察到死亡或远处复发。影像学隐匿性DCIS对IORT来说是一项挑战,对所有形式的保乳治疗来说都是如此。尽管如此,91.4%的DCIS患者仅通过BCS和IORT就得到了成功治疗,需要额外治疗的患者相对较少。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验